Necrosis News
-
Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule. In preclinical testing, RaniPill HC demonstrated successful delivery of adalimumab and achieved high bioavailability. “The ...
-
Creative Proteomics Cytokine Unveils Tumor Necrosis Factors (TNF) Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced the launch of the high-sensitivity Tumor Necrosis Factors (TNF) Detection Service to help with your ...
-
Creative Proteomics Cytokine Launches High-Sensitivity Inflammation Cytokines Assay to Support Your Research
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics is proud to announce the launch of the high-sensitivity inflammatory cytokine assays. These assays offer ultra-sensitivity, excellent ...
-
Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. Cytokines, ...
-
LISCure Biosciences received clinical approval for two microbiome programs targeting autoimmune disease and NASH
LISCure Biosciences ("LISCure") announced that it has received approval for a global phase 1 clinical trial for two programs, LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. This achievement is significant in that it will be the first global clinical trial among the microbiome treatments for rheumatoid arthritis and NASH indications. The most ...
-
Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases
Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Dr. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the novel technology during the Gene & Cell Therapy Spotlight session. The company’s ...
By Eyevensys
-
Collaborative project sets the stage for improved IHNV resistance through genomic selection
High mortality. Disrupted production schedules. Wasted feed and resources. These are some of the damaging effects of Infectious Hematopoietic necrosis virus (IHNV) in the trout industry. Infectious diseases are the largest cause of production-related mortality, accounting for 90% of the total losses in 2017 in the US. IHNV is among the most harmful to the industry; however, there are ...
-
ProUroCare Announces Agreement for the Development of Real-Time Imaging System
ProUroCare Medical, Inc. (OTC BB: PRRC.OB) has entered into a co-development agreement with Urologix ®, Inc. (NASDAQ:ULGX) and Rensselaer Polytechnic Institute to develop a real-time temperature imaging system, ProUroVision™, to be utilized with Urologix’ Cooled ThermoTherapy™ treatment of benign prostatic hyperplasia (BPH) as well as potential new indications. Cooled ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you